Huawei Has Made Another Visit to Hybio Pharmaceutical, Aiming to Explore New Opportunities in Ai-Driven Drug Discovery
On February 14, the technical team of Huawei once again visited Hybio Pharmaceutical. Both parties conducted in-depth exchanges on cutting-edge technologies and application prospects in the field of AI-driven Drug Discovery, and jointly explored the broad development space for the integration of AI and pharmaceuticals.
Dai Yunlong, representative of Huawei's Shenzhen Government and Enterprise Biomedical Industry, and Xing Heyun, Chief Architect of Biomedical Solutions at Huawei's Intelligent Manufacturing Corps, led a 7-member team for the visit, which included professionals such as biomedical industry solution architects, intelligent collaboration product managers, and computing product managers from Huawei's Intelligent Manufacturing Corps. Zeng Shaogui, Chairman and President of Hybio Pharmaceutical, extended a warm reception, and 14 relevant department heads from the company participated in the exchange, including directors, executive presidents, vice presidents, as well as those in charge of R&D, quality, registration, and enterprise management information.
During the discussions, Huawei's technical team and Hybio Pharmaceutical's R&D core personnel focused on in-depth deliberations regarding the application details of Huawei Cloud's Pangu drug molecule large model in Peptide Drug research and development. Both parties explored how to leverage the data analysis capabilities of the Pangu large model to rapidly screen peptide sequences with high activity and low toxicity, break through the limitations of traditional R&D models, and enhance R&D efficiency and success rates. They conducted in-depth exchanges on relevant topics and formulated systematic plans for subsequent work and actions. With the continuous advancement of AI technology, its application prospects in the pharmaceutical field are becoming increasingly broad.
The integration of AI and pharmaceuticals not only accelerates the drug R&D process but also reduces R&D costs and improves drug quality, bringing multiple advantages to the pharmaceutical industry. This exchange demonstrated both parties' shared commitment to exploring the field of AI-driven drug discovery and provided new ideas and directions for the future integrated development of the industry.